Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 5/20 | 0.38 |
| ▸ | FURIN | P09958 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.35 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.34 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | MPL | P40238 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21005896 | 1.00 | TRPV4 (0.38) | TRPV4FURINADORA3BMPR1BBMPR1A | |
| SCHEMBL18724206 | 0.93 | TRPV4 (0.37) | TRPV4FURINADORA3BMPR1BBMPR1A | |
| SCHEMBL17390800 | 0.90 | ADORA3 (0.43) | TRPV4ADORA3MPL | |
| SCHEMBL18724205 | 0.90 | TRPV4 (0.36) | TRPV4FURINBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL18724056 | 0.89 | MPL (0.40) | TRPV4FURINADORA3BMPR1BBMPR1A | |
| SCHEMBL18724540 | 0.89 | TRPV4 (0.35) | TRPV4FURINBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL18724449 | 0.89 | TRPV4 (0.35) | TRPV4FURINBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL18724050 | 0.88 | TRPV4 (0.37) | TRPV4FURINFGFR1MPLTMEM97 | |
| SCHEMBL17400648 | 0.88 | ADORA3 (0.42) | TRPV4ADORA3MPL | |
| SCHEMBL18724391 | 0.88 | FURIN (0.35) | TRPV4FURINADORA3BMPR1BBMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49111-E1 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2022-06-21 | — | — | US | disclosed |
| EP-3153511-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF BLADDER/URINARY TRACT DISEASES | ASTELLAS PHARMA INC (JP) | 2019-05-15 | — | — | EP | disclosed |
| US-9951060-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-20170197955-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
| EP-3153511-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2017-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197955-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, TRPM2 | TRPV4 24/4885FURIN 2275/4885ADORA3 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.